The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2024
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Samoilova Iu.G.

Siberian State Medical University

Matveeva M.V.

Siberian State Medical University

Stankova A.E.

Siberian State Medical University

Podchinenova D.V.

Siberian State Medical University

Kudlay D.A.

First Moscow State Medical University (Sechenov University);
Lomonosov Moscow State University;
State Scientific Center «Institute of Immunology»

Vaizova O.E.

Siberian State Medical University

Grishkevich I.R.

Siberian State Medical University

Effect of genetic polymorphisms on the effectiveness and safety of sodium-glucose co-transporter 2 inhibitors in treatment of type 2 diabetes mellitus

Authors:

Samoilova Iu.G., Matveeva M.V., Stankova A.E., Podchinenova D.V., Kudlay D.A., Vaizova O.E., Grishkevich I.R.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2024;27(1): 67‑71

DOI: 10.17116/profmed20242701167

Views: 621

Downloaded: 33

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Samoilova IuG, Matveeva MV, Stankova AE, Podchinenova DV, Kudlay DA, Vaizova OE, Grishkevich IR. Effect of genetic polymorphisms on the effectiveness and safety of sodium-glucose co-transporter 2 inhibitors in treatment of type 2 diabetes mellitus. Russian Journal of Preventive Medicine. 2024;27(1):67‑71. (In Russ.)
https://doi.org/10.17116/profmed20242701167

Подписка 2025 (Russian Journal of Preventive Medicine)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Type 2 diabetes mellitus and COVID-19: lethality predictors. Russian Journal of Preventive Medi­cine. 2023;(11):53-56
Main causes of premature mortality due to obesity. Russian Journal of Preventive Medi­cine. 2023;(12):52-57
Pharmacogenetics of glucagon-like peptide-1 agonists in the treatment of type 2 diabetes mellitus. Russian Journal of Preventive Medi­cine. 2023;(12):95-100
Some gene­tic markers asso­ciated with COVID-19 course seve­rity in humans. Russian Journal of Preventive Medi­cine. 2023;(12):121-127
Oxidative stress prevention as an effe­ctive preventive stra­tegy in type 2 diabetes mellitus. Russian Journal of Preventive Medi­cine. 2024;(3):117-123
Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Russian Journal of Evidence-Based Gastroenterology. 2023;(4):103-108
The role of poly­morphism rs148982377 of the ZNF789 gene in the formation of infe­rtility in patients with endo­metriosis. Russian Journal of Human Reproduction. 2024;(1):64-71
Obesity grade I: a study of real clinical practice in the Russian Fede­ration. Medi­cal Technologies. Asse­ssment and Choice. 2024;(1):83-90
Dyna­mics of outpatient glycemic profile data in patients with type 2 diabetes receiving dietary fiber. Russian Journal of Evidence-Based Gastroenterology. 2024;(2):55-65

The review presents pharmacogenetic data proving the relationship of genetic polymorphisms of genes with the effectiveness of treatment by sodium-glucose co-transporter 2 inhibitors (SGLT2-Is) in patients with type 2 diabetes mellitus. The search of publications was carried out in the PubMed database from 2017 to 2023. Polymorphisms of some genes (SLC5A2, PNPLA3, UGT1A9) have been potentially associated with the SGLT2-Is efficacy, but obtained results do not suggest their importance for clinical practice. Further studies are necessary.

Keywords:

polymorphisms
SGLT2-Is
type 2 diabetes mellitus

Authors:

Samoilova Iu.G.

Siberian State Medical University

Matveeva M.V.

Siberian State Medical University

Stankova A.E.

Siberian State Medical University

Podchinenova D.V.

Siberian State Medical University

Kudlay D.A.

First Moscow State Medical University (Sechenov University);
Lomonosov Moscow State University;
State Scientific Center «Institute of Immunology»

Vaizova O.E.

Siberian State Medical University

Grishkevich I.R.

Siberian State Medical University

Received:

02.11.2023

Accepted:

14.12.2023

List of references:

  1. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Research and Clinical Practice. 2022;183:109119. https://doi.org/10.1016/j.diabres.2021.109119
  2. Mannino GC, Andreozzi F, Sesti G. Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine. Diabetes and Metabolism Research and Reviews. 2019;35(3):e3109. https://doi.org/10.1002/dmrr.3109
  3. Kramer CK, Zinman B. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes. Annual Review of Medicine. 2019;70:323-334.  https://doi.org/10.1146/annurev-med-042017-094221
  4. Feingold KR. Oral and Injectable (Non-Insulin) Pharmacological Agents for the Treatment of Type 2 Diabetes. 2022. In: Feingold KR, Anawalt B, Blackman MR, et al., eds. South Dartmouth (MA): MDText.com, Inc.; 2000.
  5. Thomas MC, Cherney DZI. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 2018;61(10):2098-2107. https://doi.org/10.1007/s00125-018-4669-0
  6. Powell DR, Zambrowicz B, Morrow L, et al. Sotagliflozin decreases postprandial glucose and insulin concentrations by delaying intestinal glucose absorption. The Journal of Clinical Endocrinology and Metabolism. 2020; 105(4):e1235-e1249. https://doi.org/10.1210/clinem/dgz258
  7. Io F, Gunji E, Koretsune H, et al. SGL5213, a novel and potent intestinal SGLT1 inhibitor, suppresses intestinal glucose absorption and enhances plasma GLP-1 and GLP-2 secretion in rats. European Journal of Pharmacology. 2019;853:136-144.  https://doi.org/10.1016/j.ejphar.2019.03.023
  8. Zhang Y, Xie P, Li Y, et al. Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches. Frontiers in Pharmacology. 2023;14:1142003. https://doi.org/10.3389/fphar.2023.1142003
  9. Cherney DZ, Kanbay M, Lovshin JA. Renal physiology of glucose handling and therapeutic implications. Nephrology, Dialysis, Transplantation. 2020; 35(suppl 1):i3-i12.  https://doi.org/10.1093/ndt/gfz230
  10. Maloney A, Rosenstock J, Fonseca V. A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses. Clinical Pharmacology and Therapeutics. 2019; 105:1213-1223. https://doi.org/10.1002/cpt.1307
  11. Sanchez-Garcia A, Simental-Mendia M, Millan-Alanis JM, et al. Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials. Pharmacological Research. 2020;160:105068. https://doi.org/10.1016/j.phrs.2020.105068
  12. Kanie T, Mizuno A, Takaoka Y, et al. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. The Cochrane Database of Systematic Reviews. 2021;10(10):CD013650. https://doi.org/10.1002/14651858.CD013650.pub2
  13. Yamada T, Wakabayashi M, Bhalla A, et al. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovascular Diabetology. 2021;20(1):14.  https://doi.org/10.1186/s12933-020-01197-z
  14. Raj H, Durgia H, Palui R, et al. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review. World Journal of Diabetes. 2019;10(2):114-132.  https://doi.org/10.4239/wjd.v10.i2.114
  15. Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2023;381:e074068. https://doi.org/10.1136/bmj-2022-074068
  16. Puckrin R, Saltiel MP, Reynier P, et al. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetologica. 2018;55(5):503-514.  https://doi.org/10.1007/s00592-018-1116-0
  17. Patel K, Nair A. A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis. Cureus. 2022;14(9):e29652. https://doi.org/10.7759/cureus.29652
  18. Nasykhova YA, Tonyan ZN, Mikhailova AA, et al. Pharmacogenetics of Type 2 Diabetes-Progress and Prospects. International Journal of Molecular Sciences. 2020;21(18):6842. https://doi.org/10.3390/ijms21186842
  19. Eriksson JW, Lundkvist P, Jansson PA, et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 2018;61(9):1923-1934.
  20. Zimdahl H, Haupt A, Brendel M, et al. Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes. Pharmacogenetics and Genomics. 2017;27(4):135-142. 
  21. Rathmann W, Bongaerts B. Pharmacogenetics of novel glucose-lowering drugs. Diabetologia. 2021;64(6):1201-1212. https://doi.org/10.1007/s00125-021-05402-w
  22. Klen J, Dolžan V. Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations. International Journal of Molecular Sciences. 2021;22(18):9800. https://doi.org/10.3390/ijms22189800
  23. Francke S, Mamidi RN, Solanki B, et al. In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans. Journal of Clinical Pharmacology. 2015;55:1061-1072. https://doi.org/10.1002/jcph.506
  24. Kaur P, Behera BS, Singh S, Munshi A. The pharmacological profile of SGLT2 inhibitors: Focus on mechanistic aspects and pharmacogenomics. European Journal of Pharmacology. 2021;904:174169. https://doi.org/10.1016/j.ejphar.2021.174169
  25. Pereira MJ, Lundkvist P, Kamble PG, et al. A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss. Diabetes Therapy: Research, Treatment and Education of Diabetes and Related Disorders. 2018;9(4):1511-1532. https://doi.org/10.1007/s13300-018-0449-6

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.